Year: 2021

Skippack, PA, Nov. 04, 2021 (GLOBE NEWSWIRE) — North Bay Resources Inc. (OTC: NBRI) (“North Bay” or the “Company”) is pleased to announce that lab results from recent fieldwork at the Company’s 100% owned Tulameen Platinum Project in southeastern British Columbia confirms prior assessments.  Assay results from ALS Labs in Vancouver show average magnesium yields of 26.45%, which is entirely consistent with previous reports.  As well, assays as high as 0.19 grams per tonne platinum, 0.15% nickel, 0.31% chromium, 0.014% cobalt, and 0.16% manganese were also reported. During the recent fieldwork our geological team has also successfully identified and mapped a suitable location to extract a 10,000 tonne bulk sample as part of a mining permit application the Company intends to prepare and file in the near future. We note that magnesium...

Results from five patients showed best responses of 2 partial responses (PR), 1 complete response with incomplete hematological recovery (CRi) and 1 complete response (CR). Updated data show continued favorable safety profile and encouraging anti-tumor activity in adult patients treated with low doses of KUR-502. Study continues to accrue to higher doses. BUFFALO, N.Y., Nov. 04, 2021 (GLOBE NEWSWIRE) — Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today data from the ANCHOR Phase 1 study of KUR-502 to be highlighted in a poster presentation at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, being held from December 11th to December 14th,...

VANCOUVER, British Columbia, Nov. 04, 2021 (GLOBE NEWSWIRE) — Liquid Media Group Ltd. (the “Company,” “Liquid Media” or “Liquid”) (Nasdaq: YVR) today announced that iNDIEFLIX, a member of the Liquid Media family of companies, has promoted Christine Laskin to the position of Chief Operating Officer (COO). With the company for more than one year to date, Laskin has been successfully applying her wealth of growth-oriented experience to help iNDIEFLIX flourish. Her earlier background includes significant success working on asset management teams in the US and internationally as well as managing sales and product teams. In addition to past roles with Morgan Stanley, Delaware Investments, SEI Investments and InvestorForce, Laskin is currently the volunteer Executive Director of the non-profit organization Joan Karff’s Women on the Way...

NEW YORK, Nov. 04, 2021 (GLOBE NEWSWIRE) — Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a gene-editing company with clinical-stage immuno-oncology programs using allogeneic chimeric antigen receptor (CAR)-T cells and gene therapy programs for genetic diseases, today announced the release of two abstracts, which were accepted for presentation at the 63rd American Society of Hematology (ASH) Annual Meeting taking place from December 11-14, 2021. The Company will present updated preliminary clinical data from its BALLI-01 clinical trial in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), and preclinical data for TALGlobin01 for patients with HbSS Sickle Cell Disease (SCD). “2021 has been a busy and productive year for Cellectis, with our proprietary clinical and preclinical...

SEATTLE, Nov. 04, 2021 (GLOBE NEWSWIRE) — Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that data will be presented during four poster presentations at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, to be held both in person in Atlanta, GA and virtually from Sunday, December 11 to Tuesday, December 14, 2021. “We are excited to share data at ASH that showcase scientific advancements from our in vivo CAR T and ex vivo allogeneic CAR T cell programs,” said Steve Harr, Sana’s President and CEO. “These presentations and publications mark the growth of our science and our continued progress toward the clinic, as we intend to file our first IND as early as next year. We celebrate our scientists as they work toward our mission...

Media Release Copenhagen, Denmark, November 4, 2021Poster presentations highlighting safety and preliminary efficacy data of epcoritamab (DuoBody®-CD3xCD20) in combination with other treatments in patients with B-cell non-Hodgkin lymphoma (NHL) Poster presentation highlighting preliminary data from clinical trial evaluating epcoritamab in patients with chronic lymphocytic leukemia (CLL) More than 20 abstracts evaluating Genmab owned and partnered programs accepted for presentation at ASH Genmab to host virtual 2021 R&D Update and ASH Data Review meeting December 14Genmab A/S (Nasdaq: GMAB) announced today that multiple abstracts evaluating several investigational medicines in the company’s pipeline, or created using Genmab’s innovative drug development platforms, will be presented at the 63rd Annual Meeting and Exposition of...

Derived from Affimed’s ROCK® platform, AFM28 binds selectively and with high affinity the surface antigens CD123 and CD16A AFM28 shows better killing of primary leukemic blasts in comparison to monoclonal antibodies which may lead to enhanced ADCC in patients In a preclinical toxicology study AFM28 was safe and well-tolerated and exhibited the expected pharmacodynamic activity The high affinity of AFM28 to CD16A is well suited for the combination with allogeneic NK cells The AFM28 program is planned to advance to an IND filing in the first half of 2022; a clinical study is expected to begin in the second half of 2022 The clinical program will investigate AFM28 as treatment designed to address the needs of patients with Acute Myeloid Leukemia (AML) and other CD123+ myeloid malignancies, such as high-risk Myelodysplastic Syndrome (HR-MDS)HEIDELBERG,...

ALPHA2 Study Abstract Selected for Oral Presentation Highlights the Benefits of Consolidation Dosing with ALLO-501A in Patients with Relapsed/Refractory Large B Cell Lymphoma ALPHA Study Abstract Selected for Poster Presentation Continues to Show Durability of Responses to ALLO-501 in Patients with Non-Hodgkin Lymphoma UNIVERSAL Study Abstract Selected for Oral Presentation Reports Meaningful Activity of a Single Dose of ALLO-715 in Patients with Relapsed/Refractory Multiple Myeloma Presentations Scheduled for December 13, 2021SOUTH SAN FRANCISCO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer today announced that it will present updated data from its blood cancer portfolio...

Recruiting mission-driven start-up snack brands committed to a positive impact on social, environmental and human well-being Participating start-ups will receive a $20,000 grant and participate in a 12-week growth-centric curriculum led by SnackFutures Call for submissions is now open at www.snackfutures.comCHICAGO, Nov. 04, 2021 (GLOBE NEWSWIRE) — SnackFutures, the Mondelēz International, Inc. (Nasdaq: MDLZ) innovation and venture hub, today announced the opening of applications for its CoLab 2022 class. The second year of the start-up engagement program will specifically focus on mission-driven brands that can demonstrate their commitment to having a positive impact on social, environmental and human well-being. “We are thrilled to launch CoLab 2022, and particularly excited about bringing in mission-driven brands because...